News Update
The Key to Policy Change
Health Evolution's David Brailer (also a member of the Duke-Margolis Advisory Board) sat down with director Mark McClellan to discuss the next iteration of the value equation to include prescription drugs, devices and gene therapies.
David Brailer of Health Evolution sits down with Mark McClellan of the Duke-Margolis Center for Health Policy to dive deep into the next iteration of the value equation to include prescription drugs, devices and gene therapies.
The Key to Policy Change
David Brailer of Health Evolution sits down with Mark McClellan of the Duke-Margolis Center for Health Policy to dive deep into the next iteration of the value equation to include prescription drugs, devices and gene therapies.
The Key to Policy Change
David Brailer of Health Evolution sits down with Mark McClellan of the Duke-Margolis Center for Health Policy to dive deep into the next iteration of the value equation to include prescription drugs, devices and gene therapies.